HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis
Curated pathway from expert analysis
flowchart TD
A["HDAC6<br/>Inhibition"]
B["Alpha-tubulin<br/>Acetylation Increase"]
C["Microtubule<br/>Stabilization"]
D["Autophagy<br/>Flux Restoration"]
E["Proteostasis<br/>Improvement"]
F["Pan-neurodegenerative<br/>Protein Clearance"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for HDAC6 yet. Search RCSB →
Median TPM across 13 brain regions for HDAC6 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HDAC6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early-stage Parkinson's disease patients receive HDAC6 inhibitor (ACY-738 or equivalent) at 50mg twice daily for 24 weeks, THEN CSF α-synuclein aggregate clearance rate will increase by ≥25% compar | ≥25% increase in α-synuclein clearance rate; stabilization or reduction of CSF NfL levels | — no observation — | pending | 0.35 |
| IF 5xFAD mice (Alzheimer's model) receive chronic HDAC6 inhibitor (tubastatin A, 10mg/kg/day) via osmotic pump for 8 weeks starting at 3 months of age, THEN soluble aggregated tau levels in cortical t | ≥30% reduction in soluble hyperphosphorylated tau aggregates in cortical brain regions | — no observation — | pending | 0.45 |